403 related articles for article (PubMed ID: 24645735)
1. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Andoh T; Yoshida T; Kuraishi Y
Exp Dermatol; 2014 May; 23(5):359-61. PubMed ID: 24645735
[TBL] [Abstract][Full Text] [Related]
2. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP.
Andoh T; Kuraishi Y
J Dermatol Sci; 2014 Dec; 76(3):206-13. PubMed ID: 25458869
[TBL] [Abstract][Full Text] [Related]
3. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
4. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Wakita H; Ohkuro M; Ishii N; Hishinuma I; Shirato M
Exp Dermatol; 2015 Mar; 24(3):215-6. PubMed ID: 25431172
[TBL] [Abstract][Full Text] [Related]
5. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.
Furue M; Kadono T; Tsuji G; Nakahara T
Expert Opin Investig Drugs; 2017 Dec; 26(12):1403-1408. PubMed ID: 29068253
[TBL] [Abstract][Full Text] [Related]
6. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.
Ishii N; Wakita H; Shirato M
J Dermatol Sci; 2014 Dec; 76(3):263-4. PubMed ID: 25455141
[No Abstract] [Full Text] [Related]
7. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice.
Sugimoto M; Arai I; Futaki N; Hashimoto Y; Sakurai T; Honma Y; Nakaike S
Eur J Pharmacol; 2007 Jun; 564(1-3):196-203. PubMed ID: 17328887
[TBL] [Abstract][Full Text] [Related]
8. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
Nemoto O; Hayashi N; Kitahara Y; Furue M; Hojo S; Nomoto M; Shima S;
J Dermatol; 2016 Aug; 43(8):881-7. PubMed ID: 26703371
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Ohba F; Matsuki S; Imayama S; Matsuguma K; Hojo S; Nomoto M; Akama H
J Dermatolog Treat; 2016 Oct; 27(5):467-72. PubMed ID: 27080209
[TBL] [Abstract][Full Text] [Related]
10. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
Ohba F; Nomoto M; Hojo S; Akama H
J Dermatolog Treat; 2016; 27(3):241-6. PubMed ID: 26581111
[TBL] [Abstract][Full Text] [Related]
13. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis.
Takano N; Arai I; Kurachi M
Eur J Pharmacol; 2003 Jun; 471(3):223-8. PubMed ID: 12826242
[TBL] [Abstract][Full Text] [Related]
15. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
Soeberdt M; Kilic A; Abels C
Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692
[TBL] [Abstract][Full Text] [Related]
16. Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.
Ko KC; Tominaga M; Kamata Y; Umehara Y; Matsuda H; Takahashi N; Kina K; Ogawa M; Ogawa H; Takamori K
Acta Derm Venereol; 2016 Jun; 96(5):624-9. PubMed ID: 26671728
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.
Inagaki N; Shiraishi N; Igeta K; Itoh T; Chikumoto T; Nagao M; Kim JF; Nagai H
Eur J Pharmacol; 2006 Sep; 546(1-3):189-96. PubMed ID: 16914137
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
Kitahara Y; Hojo S; Nomoto M; Onozuka D; Furue M; Hagihara A
J Dermatolog Treat; 2019 Aug; 30(5):466-470. PubMed ID: 30265585
[No Abstract] [Full Text] [Related]
19. Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.
Terakawa M; Fujieda Y; Tomimori Y; Muto T; Tanaka T; Maruoka H; Nagahira K; Ogata A; Nakatsuka T; Fukuda Y
Eur J Pharmacol; 2008 Dec; 601(1-3):186-91. PubMed ID: 18996112
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.
Tanizaki H; Kambe N; Nakamura Y; Tanaka A; Matsuda H; Miyachi Y
Int Arch Allergy Immunol; 2008; 145(4):277-82. PubMed ID: 18004068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
